
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is positioned for revenue growth through 2030, driven by factors such as lower Invega royalties and patent expiries, complemented by the acquisition of Lumryz, which is expected to generate annualized sales of approximately $265-$275 million by 2025. The company anticipates further growth with potential annual revenues from Lumryz expanding into narcolepsy and idiopathic hypersomnia, projected to reach around $550 million and $250 million, respectively, in out-years following expected clinical milestones. Additionally, the encouraging data for alixorexton and the strategic acquisition of AVDL are expected to bolster both near- and mid-term growth opportunities without straining the company's balance sheet.
Bears say
Alkermes PLC faces a negative outlook primarily due to anticipated declines in Lumryz sales after reaching approximately $600 million in 2030, along with the loss of exclusivity in 2037, which will significantly impact revenue generation. Additionally, the company's reliance on early-stage orexin data raises concerns regarding efficacy and safety, alongside risks associated with Medicaid exposure amid changing administration policies. Lastly, increasing competition within the narcolepsy treatment landscape, particularly with multiple orexin 2 receptor agonists, is expected to lead to eroded market share and stagnant growth for the Lumryz franchise.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares